Results 171 to 180 of about 22,784 (283)

A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors. [PDF]

Front Immunol, 2019
Izumi K, Nishie W, Beniko M, Shimizu H.
europepmc   +1 more source

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [PDF]

, 2016
Daisuke Koya, Keizo Kanasaki, Sen Shi
core   +1 more source

Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins [PDF]

, 2013
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar, Félix M. Goñi   +9 more
openalex   +1 more source

A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 205-213, February 2026.
Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, was evaluated in a Phase 1, double‐blind, placebo‐controlled, randomized, single and multiple ascending dose study in Japanese participants with type 2 diabetes. The safety and tolerability profile of orforglipron was consistent with those of other GLP‐1 receptor agonists, and ...
Kenji Ohwaki, Chino Nakamura, Risa Nasu, Kazumasa Takenouchi, Tetsuaki Hirase   +4 more
wiley   +1 more source

Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. [PDF]

J Clin Med, 2018
Kim YG, Jeon JY, Kim HJ, Kim DJ, Lee KW, Moon SY, Han SJ.   +6 more
europepmc   +1 more source

The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes

, 2015
Chia‐Ling Jao, Chuan-Chuan Hung, Yu-Shan Tung, Pei‐Yi Lin, Mengchun Chen, Kuo‐Chiang Hsu   +5 more
openalex   +1 more source

The difference in type 2 diabetes care between the National Health Insurance beneficiaries and public assistance recipients in Japan: A retrospective cohort study based on claims data in a municipality

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 347-359, February 2026.
We examined the differences in type 2 diabetes care between public assistance recipients and National Health Insurance beneficiaries in Japan by using claims data from a municipality. Public assistance might improve diabetes care process, but not fully health outcomes.
Takuya Yamaoka, Takehiro Sugiyama, Daisuke Nishioka, Naoki Kondo, Nanako Tamiya   +4 more
wiley   +1 more source

In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies. [PDF]

In Silico Pharmacol, 2017
Sharma MC, Jain S, Sharma R.
europepmc   +1 more source

Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 214-226, February 2026.
Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement.
Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki   +4 more
wiley   +1 more source

Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV

, 2014
Kenji Namoto, Finton Sirockin, Nils Ostermann, F. Gessier, Stefanie Flohr, Richard Sedrani, Bernd Gerhartz, Jörg Trappe, Ulrich Hassiepen, Alokesh Duttaroy, Suzie A. Ferreira, Jon M. Sutton, David E. Clark, Garry Fenton, Mandy Beswick, Daniel K. Baeschlin   +15 more
openalex   +1 more source